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Microvascular Dysfunction and Post-PCI Ischemia among Anti-
Platelet and Anti-Thrombotic Agents–Thrombolysis In Myocar-
dial Infarction-30) trial, in which patients with moderate to
high-risk acute coronary syndrome (ACS) undergoing percutane-
ous coronary intervention (PCI) were randomly allocated to receive
eptifibatide with either unfractionated heparin or enoxaparin
versus bivalirudin monotherapy. Although this study adds insight-
ful information to the ongoing debate on the comparison of direct
thrombin inhibitor alone versus the association of glycoprotein
(GP) IIb/IIIa inhibitors and indirect antithrombin agents as
adjunctive treatment during PCI, it also puzzles the reader with
the contrasting data on efficacy provided by the primary and
secondary end points.
The post-PCI coronary flow reserve (CFR), quantified through
the corrected Thrombolysis In Myocardial Infarction (TIMI)
frame count, has to the best of our knowledge never been shown to
correlate with outcomes in patients with non–ST-segment eleva-
tion ACS. Moreover, its agreement with Doppler-derived CRF in
this setting has been questioned (2). In contrast, the 25% relative
risk reduction in the composite of death or myocardial infarction
(MI) at 48 h and the significant 35% relative decrease in the rate
of patients showing post-PCI creatine kinase-myocardial band
(CK-MB) elevation among subjects (n  624; 73%) CK-MB–
negative at baseline in the group allocated to eptifibatide seem to
support the additive value of complete platelet inhibition in such a
setting (3). We believe that some methodological issues beyond
those discussed by Gibson et al. (1) may help explain the
paradoxical results of the primary end point when put into the
context of the results reported for the secondary outcomes.
Coronary flow reserve after the procedure could not be analyzed
according to the intention-to-treat principle in the study because
patients who sustained abrupt vessel closure, emergent coronary
bypass graft surgery, or thrombotic closure with bailout to eptifi-
batide had to be excluded (n  103; 12% of the enrolled
population). It thus remains possible that patients at relatively
lower risk have been selected for the primary end point assessment
in whom no or minor benefit from GP IIb/IIIa inhibitors on
microcirculation may be expected. It would be of utmost interest to
know the rate of major adverse events in this excluded fraction of
patients, stratified according to the randomization scheme and as
compared to the patient group in whom primary end point analysis
could be accomplished. This may help to reconcile the apparently
contrasting data between the primary end point (based on 88% of
the enrolled population) and secondary outcome (based on the
whole population) results in the study.
Finally, the investigators comment in the discussion section that
the risk of death or MI was significantly reduced among eptifi-
batide patients who were pretreated for 6 h with clopidogrel
before PCI, but they fail to report throughout the study the actual
figures for the observed event rates in this subset of patients despite
the fact that this was a prespecified secondary analysis and that
randomization was stratified according to prior use of thienopyri-
dines. We believe that this information may help to put
PROTECT–TIMI-30 findings in perspective, especially consid-
ering that 40% of ACS patients may undergo PCI after upfront
blockade of the P2Y12 receptor in current clinical practice (4).
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Reply
We thank Dr. Valgimigli et al. for their careful review of the
PROTECT–TIMI-30 (Randomized Trial to Evaluate the Rela-
tive PROTECTion against Post-PCI Microvascular Dysfunction
and Post-PCI Ischemia among Anti-Platelet and Anti-
Thrombotic Agents–Thrombolysis In Myocardial Infarction-30)
study (1). The corrected Thrombolysis In Myocardial Infarction
(TIMI) frame count (cTFC) measures the time that it takes for
blood to traverse the entire length of the artery and reflects the
average velocity throughout the entire length of the artery. In
contrast, a Doppler velocity wire measures the velocity at a single
point in the artery. As shown in the angiogram that accompanies
our report (1), blood velocity can vary significantly throughout the
length of the artery, and it is therefore no surprise that the cTFC
(average velocity) and Doppler velocity (velocity at a single point)
measures may be discordant in their assessment of basal blood
velocity given the heterogeneity in velocity throughout an artery.
The ability to speed up this basal blood velocity is the coronary flow
reserve (CFR). The cTFC measures how much faster blood passes
through the same length of the entire artery before and after
adenosine. In contrast, a Doppler velocity wire measures whether the
velocity accelerated at a single point in the artery. As opposed to
potential discrepancies in basal velocity, the CFR based on the cTFC
has been related to Doppler velocity measures (r  0.88) (2).
Although the basal cTFC has been related to mortality and
post-percutaneous coronary intervention (PCI) events, Valgimigli
et al. correctly point out that CFR by the cTFC method has not
been related to clinical outcomes (3), and it should be added that
Doppler velocity measures have not been related to outcomes as
well. In contrast, the TIMI myocardial perfusion grade (TMPG)
was related to ischemic and clinical outcomes following PCI (3).
Dr. Valgimigli et al. point out that CFR could not be assessed
in patients with a failed PCI procedure in whom there was abrupt
vessel closure, emergency coronary artery bypass graft surgery, or
thrombotic closure with bailout to eptifibatide. To account for
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these failed procedures, an additional analysis was stated a priori in
detail in the statistical analysis plan prior to unblinding in which
the lowest (i.e., worst) CFR from the prior ESPRIT (Enhanced
Suppression of the Platelet IIb/IIIa Receptor with Integrilin
Therapy) substudy (0.55) was imputed to those patients with a
failed procedure. When patients with a failed procedure were
included in the analysis, no difference was seen between bivalirudin
and eptifibatide in the primary end point (median of 1.43 for
bivalirudin vs. 1.33 for pooled eptifibatide arms, p  0.13). To
comply with the requests of the reviewers, however, the analysis in
the published report included only patients with a successful PCI
and does not account for patients with a failed procedure.
Given the potential for clopidogrel pretreatment to confound
the efficacy outcomes in the trial, randomization in the trial was
stratified by clopidogrel pretreatment, and it was prespecified that
the key analyses would be adjusted for clopidogrel pretreatment. In
a prespecified analysis, there was a significant interaction term
between clopidogrel pretreatment and the randomization arm with
respect to the end point of death or myocardial infarction (MI)
(p  0.031 for interaction between clopidogrel pretreatment and
randomization arm). Among patients treated with clopidogrel for
6 h before angiography, the risk of death/MI was significantly
lower among patients treated with eptifibatide compared with
bivalirudin (5.0% vs. 10.3%, n  548, p  0.022). In the smaller
cohort of 309 patients treated with clopidogrel for 6 h, no
significant difference existed in the incidence of death/MI between
eptifibatide and bivalirudin (9.5% vs. 6.1%, p  0.31). Among
troponin-positive patients treated for 6 h with clopidogrel, the
risk of death/MI was significantly lower among patients treated
with eptifibatide (4.1%, n  197 vs. 13.2%, n  106, p  0.003).
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Taser Research
in Pigs Not Helpful
Two reports in a 2006 issue of JACC cite studies of the effects of
Taser shocks in porcine “models.” Nanthakumar et al. (1) reported
the results of 150 discharges at various body locations in 6 pigs,
concluding that there may be increased risks for dysrhythmias,
especially under conditions of adrenergic stress. Lakkireddy et al.
(2) reported the results of shocks in 5 pigs before and after cocaine
infusions, using a device designed to mimic the Taser X-26 model.
Cocaine increased the ventricular fibrillation (VF) threshold in
these pigs, suggesting cocaine may be protective for Taser-related
VF risk in humans.
Efforts to study the human effects of Taser shocks by substitut-
ing pigs appear to have little rationale or necessity. Important
anatomical and electrophysiological differences between humans
and pigs make pigs poor surrogates for human responses to cardiac
drugs and electrical discharges. Additional confounders include the
use of anesthesia, controlled laboratory conditions, repetitive
shocks in animals smaller than humans, and inability to interview
the subjects about symptoms caused by their Taser exposures.
Nanthakumar et al.’s (1) finding of increased Taser-associated
dysrhythmia risk in pigs contrasts with a 2005 study in healthy human
volunteers (3), and is not supported by a review of many thousands of
Taser outcomes in police uses and in human volunteers (4). Lak-
kireddy et al.’s (2) conclusion contradicts the known effects of cocaine
on dysrhythmia risk in humans (5,6).
The effects of Taser shocks in humans may not be completely
understood, but the useful information to date is from studies in
humans receiving shocks under various circumstances. Conflicting
and inconsistent results from studies in pigs and other animals have
muddied rather than clarified the picture. No scientific or ethical
justification exists for such studies when much species-specific
information is available and could be expanded (7).
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